Fenugreek for Type 2 Diabetes

Verdict: Modestly lowers blood sugar; evidence preliminary

Fenugreek appears to produce a modest reduction in long-term blood sugar (HbA1c) in people with type 2 diabetes, but the evidence is preliminary and inconsistent. At best it is a possible add-on, not a substitute for proven diet, exercise, or medication.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

Five meta-analyses (PMIDs 39286181, 37762302, 36837450, 38846904, 27496582) consistently point the same way, reporting statistically significant drops in HbA1c of roughly 0.5 to 1.2 percentage points along with lower fasting glucose, and two double-blind RCTs (PMIDs 34466512, 38863744) agree. That consistent positive signal is why fenugreek earns a B rather than a lower grade.

But the quality is mixed, so it stays preliminary. Fasting-glucose results were extremely heterogeneous (I-squared 99% in PMID 36837450, where the pooled fasting effect was not even significant), the largest HbA1c effect (PMID 27496582, -1.16%) looks like an outlier from older, smaller trials, and most studies were small, run mainly in South Asian populations, and added fenugreek on top of existing diabetes drugs. The most favorable trial (PMID 38863744) tested a patented extract, was partly industry-funded, and used inflated percentage-change figures (HbA1c -34.7%).

Regulators and clinicians are notably cautious. The US FDA lists fenugreek only as a flavoring agent with no approved diabetes claim, EU EFSA rejected a fenugreek blood-sugar health claim, and the WHO monograph calls diabetes use traditional and 'not yet proven by clinical data.' NIH ODS and Cleveland Clinic advise caution, and diabetes specialty guidance does not recommend herbs for glycemic control. Because fenugreek can add to the effect of diabetes medications, anyone considering it should consult a clinician to avoid hypoglycemia.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.56
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
74%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.25
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.565
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (5 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (7)L2 · primary research & systematic reviews

Therapeutic effect of fenugreek supplementation on type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials
PMID: 39286181 2024 統合分析 n = 19
Finding: Fenugreek significantly reduced FPG by WMD -20.32 mg/dL (95% CI: -26.65 to -13.99) and HbA1c by WMD -0.54% (95% CI: -0.80 to -0.28); no significant effect on fasting insulin or triglycerides.
🟢 High quality Effect size: FPG WMD -20.32 mg/dL; HbA1c WMD -0.54%
View on PubMed
The Effect of Fenugreek in Type 2 Diabetes and Prediabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
PMID: 37762302 2023 統合分析 n = 706
Finding: Fenugreek significantly reduced FBG, HbA1c, and 2-hPG; improved total cholesterol, triglycerides, and HDL-C; no significant effect on HOMA-IR, LDL-C, or BMI; no hepatic/renal toxicity.
🟢 High quality Academic Effect size: statistically significant reductions in FBG, HbA1c, 2-hPG (specific MDs not reported in abstract)
View on PubMed
Effect of Fenugreek on Hyperglycemia: A Systematic Review and Meta-Analysis
PMID: 36837450 2023 統合分析 n = 894
Finding: FBG reduction not significant (MD -3.70 mg/dL, 95% CI: -27.02 to 19.62, p=0.76; I²=99.37%); HbA1c significantly reduced (MD -0.88%, 95% CI: -1.49 to -0.27, p=0.004; I²=74.79%). Very high heterogeneity across FBG studies.
Effect size: FBG MD -3.70 mg/dL (ns); HbA1c MD -0.88%
View on PubMed
Enhancing glycaemic control and promoting cardiovascular health: the therapeutic potential of Trigonella foenumgraecum in diabetic patients - a systematic review and meta-analysis
PMID: 38846904 2024 統合分析
Finding: Fenugreek significantly reduced FBS (P<0.001), HbA1c (P<0.001), and postprandial glucose (P<0.001) in type 2 diabetic patients.
Effect size: statistically significant (P<0.001); specific MDs not available in abstract
View on PubMed
Effect of fenugreek on hyperglycaemia and hyperlipidemia in diabetes and prediabetes: A meta-analysis
PMID: 27496582 2016 統合分析 n = 12
Finding: Fenugreek significantly reduced FBG (MD -0.84 mmol/L, 95% CI: -1.38 to -0.31, p=0.002) and HbA1c (MD -1.16%, 95% CI: -1.23 to -1.09, p<0.00001); also significantly reduced total cholesterol; no hepatic/renal toxicity.
Effect size: FBG MD -0.84 mmol/L; HbA1c MD -1.16%
View on PubMed
Effect of Fenugreek Use on Fasting Blood Glucose, Glycosylated Hemoglobin, Body Mass Index, Waist Circumference, Blood Pressure and Quality of Life in Patients with Type 2 Diabetes Mellitus: A Rand…
PMID: 34466512 2019 RCT (double-blind) n = 62
Finding: Fenugreek group showed significant reductions in FBS and HbA1c vs. placebo (P<0.001); also improved BMI, waist circumference, diastolic BP, and quality of life.
Effect size: P<0.001 for FBS and HbA1c (specific MD not reported in abstract)
View on PubMed
A randomized double blind placebo controlled trial to assess the safety and efficacy of a patented fenugreek (Trigonella foenum-graecum) seed extract in Type 2 diabetics
PMID: 38863744 2024 RCT (double-blind) n = 81
Finding: Fenfuro® reduced FBG by 38%, postprandial glucose by 44%, and HbA1c by 34.7% vs. placebo; no adverse events or significant changes in safety markers.
⚠️ Industry-funded Effect size: FBG -38%; postprandial glucose -44%; HbA1c -34.7% (relative change)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
FLAVORING AGENT OR ADJUVANT source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
葫蘆巴;希臘草 / Fenugreek, Goat horn, Cow horn / Trigonella foenum-graecum L. — 草、木本植物類(2) — 種子、葉、芽(苗) — 得作為食品之單一或主要原料 source↗
L4e WHO
Supportive
WHO Monographs on Selected Medicinal Plants, Volume 3 (Geneva, 2007): monograph "Semen Trigonellae Foenugraeci" (p. 338). Uses supported by clinical data — none listed. Uses described in traditional medicine/not yet proven by clinical data: orexigenic (loss of appetite); galactagogue; adjuvant in diabetes mellitus and mild hypercholesterolaemia. External use: local anti-inflammatory (minor skin… source↗
L5a NIH Office of Dietary Supplements
Cautious
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬7 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-type2-diabetes-INT-fenugreek-001 繁體中文版 →